Pharmicell Co., Ltd. - Product Pipeline Review - 2014

Pharmicell Co., Ltd. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. The report provides an overview of the Pharmicell Co., Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pharmicell Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Pharmicell Co., Ltd. including business description, key information and facts, and its locations and subsidiaries

- The report reviews current pipeline of Pharmicell Co., Ltd.’s human therapeutic division and enlists all their major and minor projects

- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 

- Special feature on out-licensed and partnered product portfolio

- The report summarizes all the dormant and discontinued pipeline projects

- Latest company statement 

- Latest news and deals relating to the Pharmicell Co., Ltd.’s pipeline products

Reasons to buy

- Evaluate Pharmicell Co., Ltd.’s strategic position with total access to detailed information on its product pipeline

- Assess the growth potential of Pharmicell Co., Ltd. in its therapy areas of focus

- Identify new drug targets and therapeutic classes in the Pharmicell Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

- Develop strategic initiatives by understanding the focus areas of Pharmicell Co., Ltd. and exploit collaboration and partnership opportunities

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pharmicell Co., Ltd.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Explore the dormant and discontinued projects of Pharmicell Co., Ltd. and identify potential opportunities in those areas

- Avoid Intellectual Property Rights related issues

To view the table of contents and know more details please visit Pharmicell Co., Ltd. - Product Pipeline Review - 2014

Inbiopro Solutions Pvt. Ltd. - Product Pipeline Review - 2014

Inbiopro Solutions Pvt. Ltd. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. The report provides an overview of the Inbiopro Solutions Pvt. Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Inbiopro Solutions Pvt. Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Inbiopro Solutions Pvt. Ltd. including business description, key information and facts, and its locations and subsidiaries

- The report reviews current pipeline of Inbiopro Solutions Pvt. Ltd.’s human therapeutic division and enlists all their major and minor projects

- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 

- Special feature on out-licensed and partnered product portfolio

- The report summarizes all the dormant and discontinued pipeline projects

- Latest company statement 

- Latest news and deals relating to the Inbiopro Solutions Pvt. Ltd.’s pipeline products

Reasons to buy

- Evaluate Inbiopro Solutions Pvt. Ltd.’s strategic position with total access to detailed information on its product pipeline

- Assess the growth potential of Inbiopro Solutions Pvt. Ltd. in its therapy areas of focus

- Identify new drug targets and therapeutic classes in the Inbiopro Solutions Pvt. Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

- Develop strategic initiatives by understanding the focus areas of Inbiopro Solutions Pvt. Ltd. and exploit collaboration and partnership opportunities

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Inbiopro Solutions Pvt. Ltd.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Explore the dormant and discontinued projects of Inbiopro Solutions Pvt. Ltd. and identify potential opportunities in those areas

- Avoid Intellectual Property Rights related issues

To view the table of contents and know more details please visit Inbiopro Solutions Pvt. Ltd. - Product Pipeline Review - 2014

Genethon - Product Pipeline Review - 2014

Genethon - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. The report provides an overview of the Genethon’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Genethon’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Genethon including business description, key information and facts, and its locations and subsidiaries

- The report reviews current pipeline of Genethon’s human therapeutic division and enlists all their major and minor projects

- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 

- Special feature on out-licensed and partnered product portfolio

- The report summarizes all the dormant and discontinued pipeline projects

- Latest company statement 

- Latest news and deals relating to the Genethon’s pipeline products

Reasons to buy

- Evaluate Genethon’s strategic position with total access to detailed information on its product pipeline

- Assess the growth potential of Genethon in its therapy areas of focus

- Identify new drug targets and therapeutic classes in the Genethon’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

- Develop strategic initiatives by understanding the focus areas of Genethon and exploit collaboration and partnership opportunities

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Genethon

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Explore the dormant and discontinued projects of Genethon and identify potential opportunities in those areas

- Avoid Intellectual Property Rights related issues

To view the table of contents and know more details please visit Genethon - Product Pipeline Review - 2014

Millennium Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Millennium Pharmaceuticals, Inc. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. The report provides an overview of the Millennium Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Millennium Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Millennium Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries

- The report reviews current pipeline of Millennium Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects

- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 

- Special feature on out-licensed and partnered product portfolio

- The report summarizes all the dormant and discontinued pipeline projects

- Latest company statement 

- Latest news and deals relating to the Millennium Pharmaceuticals, Inc.’s pipeline products

Reasons to buy

- Evaluate Millennium Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline

- Assess the growth potential of Millennium Pharmaceuticals, Inc. in its therapy areas of focus

- Identify new drug targets and therapeutic classes in the Millennium Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

- Develop strategic initiatives by understanding the focus areas of Millennium Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Millennium Pharmaceuticals, Inc.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Explore the dormant and discontinued projects of Millennium Pharmaceuticals, Inc. and identify potential opportunities in those areas

- Avoid Intellectual Property Rights related issues

To view the table of contents and know more details please visit Millennium Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Immunovaccine, Inc. - Product Pipeline Review - 2014

Immunovaccine, Inc. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. The report provides an overview of the Immunovaccine, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Immunovaccine, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Immunovaccine, Inc. including business description, key information and facts, and its locations and subsidiaries

- The report reviews current pipeline of Immunovaccine, Inc.’s human therapeutic division and enlists all their major and minor projects

- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 

- Special feature on out-licensed and partnered product portfolio

- The report summarizes all the dormant and discontinued pipeline projects

- Latest company statement 

- Latest news and deals relating to the Immunovaccine, Inc.’s pipeline products

Reasons to buy

- Evaluate Immunovaccine, Inc.’s strategic position with total access to detailed information on its product pipeline

- Assess the growth potential of Immunovaccine, Inc. in its therapy areas of focus

- Identify new drug targets and therapeutic classes in the Immunovaccine, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

- Develop strategic initiatives by understanding the focus areas of Immunovaccine, Inc. and exploit collaboration and partnership opportunities

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immunovaccine, Inc.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Explore the dormant and discontinued projects of Immunovaccine, Inc. and identify potential opportunities in those areas

- Avoid Intellectual Property Rights related issues

To view the table of contents and know more details please visit Immunovaccine, Inc. - Product Pipeline Review - 2014

NuCana BioMed Limited - Product Pipeline Review - 2014

NuCana BioMed Limited - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. The report provides an overview of the NuCana BioMed Limited’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of NuCana BioMed Limited’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of NuCana BioMed Limited including business description, key information and facts, and its locations and subsidiaries

- The report reviews current pipeline of NuCana BioMed Limited’s human therapeutic division and enlists all their major and minor projects

- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 

- Special feature on out-licensed and partnered product portfolio

- The report summarizes all the dormant and discontinued pipeline projects

- Latest company statement 

- Latest news and deals relating to the NuCana BioMed Limited’s pipeline products

Reasons to buy

- Evaluate NuCana BioMed Limited’s strategic position with total access to detailed information on its product pipeline

- Assess the growth potential of NuCana BioMed Limited in its therapy areas of focus

- Identify new drug targets and therapeutic classes in the NuCana BioMed Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

- Develop strategic initiatives by understanding the focus areas of NuCana BioMed Limited and exploit collaboration and partnership opportunities

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Plan mergers and acquisitions effectively by identifying the most promising pipeline of NuCana BioMed Limited

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Explore the dormant and discontinued projects of NuCana BioMed Limited and identify potential opportunities in those areas

- Avoid Intellectual Property Rights related issues

To view the table of contents and know more details please visit NuCana BioMed Limited - Product Pipeline Review - 2014

Targacept, Inc. - Product Pipeline Review - 2014

Targacept, Inc. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. The report provides an overview of the Targacept, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Targacept, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Targacept, Inc. including business description, key information and facts, and its locations and subsidiaries

- The report reviews current pipeline of Targacept, Inc.’s human therapeutic division and enlists all their major and minor projects

- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 

- Special feature on out-licensed and partnered product portfolio

- The report summarizes all the dormant and discontinued pipeline projects

- Latest company statement 

- Latest news and deals relating to the Targacept, Inc.’s pipeline products

Reasons to buy

- Evaluate Targacept, Inc.’s strategic position with total access to detailed information on its product pipeline

- Assess the growth potential of Targacept, Inc. in its therapy areas of focus

- Identify new drug targets and therapeutic classes in the Targacept, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

- Develop strategic initiatives by understanding the focus areas of Targacept, Inc. and exploit collaboration and partnership opportunities

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Targacept, Inc.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Explore the dormant and discontinued projects of Targacept, Inc. and identify potential opportunities in those areas

- Avoid Intellectual Property Rights related issues

To view the table of contents and know more details please visit Targacept, Inc. - Product Pipeline Review - 2014

Sinovac Biotech Ltd. - Product Pipeline Review - 2014

Sinovac Biotech Ltd. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. The report provides an overview of the Sinovac Biotech Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sinovac Biotech Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Sinovac Biotech Ltd. including business description, key information and facts, and its locations and subsidiaries

- The report reviews current pipeline of Sinovac Biotech Ltd.’s human therapeutic division and enlists all their major and minor projects

- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 

- Special feature on out-licensed and partnered product portfolio

- The report summarizes all the dormant and discontinued pipeline projects

- Latest company statement 

- Latest news and deals relating to the Sinovac Biotech Ltd.’s pipeline products

Reasons to buy

- Evaluate Sinovac Biotech Ltd.’s strategic position with total access to detailed information on its product pipeline

- Assess the growth potential of Sinovac Biotech Ltd. in its therapy areas of focus

- Identify new drug targets and therapeutic classes in the Sinovac Biotech Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

- Develop strategic initiatives by understanding the focus areas of Sinovac Biotech Ltd. and exploit collaboration and partnership opportunities

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sinovac Biotech Ltd.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Explore the dormant and discontinued projects of Sinovac Biotech Ltd. and identify potential opportunities in those areas

- Avoid Intellectual Property Rights related issues

To view the table of contents and know more details please visit Sinovac Biotech Ltd. - Product Pipeline Review - 2014

Aurigene Discovery Technologies Limited - Product Pipeline Review - 2014

Aurigene Discovery Technologies Limited - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. The report provides an overview of the Aurigene Discovery Technologies Limited’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Aurigene Discovery Technologies Limited’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Aurigene Discovery Technologies Limited including business description, key information and facts, and its locations and subsidiaries

- The report reviews current pipeline of Aurigene Discovery Technologies Limited’s human therapeutic division and enlists all their major and minor projects

- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 

- Special feature on out-licensed and partnered product portfolio

- The report summarizes all the dormant and discontinued pipeline projects

- Latest company statement 

- Latest news and deals relating to the Aurigene Discovery Technologies Limited’s pipeline products

Reasons to buy

- Evaluate Aurigene Discovery Technologies Limited’s strategic position with total access to detailed information on its product pipeline

- Assess the growth potential of Aurigene Discovery Technologies Limited in its therapy areas of focus

- Identify new drug targets and therapeutic classes in the Aurigene Discovery Technologies Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

- Develop strategic initiatives by understanding the focus areas of Aurigene Discovery Technologies Limited and exploit collaboration and partnership opportunities

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Aurigene Discovery Technologies Limited

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Explore the dormant and discontinued projects of Aurigene Discovery Technologies Limited and identify potential opportunities in those areas

- Avoid Intellectual Property Rights related issues

To view the table of contents and know more details please visit Aurigene Discovery Technologies Limited - Product Pipeline Review - 2014

Immune Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Immune Pharmaceuticals, Inc. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. The report provides an overview of the Immune Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Immune Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Immune Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries

- The report reviews current pipeline of Immune Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects

- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 

- Special feature on out-licensed and partnered product portfolio

- The report summarizes all the dormant and discontinued pipeline projects

- Latest company statement 

- Latest news and deals relating to the Immune Pharmaceuticals, Inc.’s pipeline products

Reasons to buy

- Evaluate Immune Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline

- Assess the growth potential of Immune Pharmaceuticals, Inc. in its therapy areas of focus

- Identify new drug targets and therapeutic classes in the Immune Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

- Develop strategic initiatives by understanding the focus areas of Immune Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immune Pharmaceuticals, Inc.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Explore the dormant and discontinued projects of Immune Pharmaceuticals, Inc. and identify potential opportunities in those areas

- Avoid Intellectual Property Rights related issues

To view the table of contents and know more details please visit Immune Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Flamel Technologies S.A. - Product Pipeline Review - 2014

Flamel Technologies S.A. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. The report provides an overview of the Flamel Technologies S.A.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Flamel Technologies S.A.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Flamel Technologies S.A. including business description, key information and facts, and its locations and subsidiaries

- The report reviews current pipeline of Flamel Technologies S.A.’s human therapeutic division and enlists all their major and minor projects

- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 

- Special feature on out-licensed and partnered product portfolio

- The report summarizes all the dormant and discontinued pipeline projects

- Latest company statement 

- Latest news and deals relating to the Flamel Technologies S.A.’s pipeline products

Reasons to buy

- Evaluate Flamel Technologies S.A.’s strategic position with total access to detailed information on its product pipeline

- Assess the growth potential of Flamel Technologies S.A. in its therapy areas of focus

- Identify new drug targets and therapeutic classes in the Flamel Technologies S.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

- Develop strategic initiatives by understanding the focus areas of Flamel Technologies S.A. and exploit collaboration and partnership opportunities

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Flamel Technologies S.A.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Explore the dormant and discontinued projects of Flamel Technologies S.A. and identify potential opportunities in those areas

- Avoid Intellectual Property Rights related issues

To view the table of contents and know more details please visit Flamel Technologies S.A. - Product Pipeline Review - 2014